Global Hepatitis A Vaccine Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030
Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year.
Two types of HAV vaccines are currently available internationally:
1. Formaldehyde-inactivated vaccines: Inactivated HAV vaccines are used in most countries. Monovalent inactivated HAV vaccines are available in paediatric dose (0.5 ml) for children aged 1 year to 15 years, and in adult dose (1 ml).
2. Live attenuated vaccines (based on H2 or LA-1 HAV strains): These vaccines are manufactured and used mainly in China and sporadically in the private sector in India.
According to APO Research, The global Hepatitis A Vaccine market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
Global Hepatitis A Vaccine key players include GSK, Merck, Sanofi, etc. Global top three manufacturers hold a share over 85%.
Europe is the largest market, with a share over 30%, followed by North America and China, both have a share about 45 percent.
In terms of product, Inactivated Vaccine is the largest segment, with a share about 70%. And in terms of application, the largest application is Government Institution, followed by Private Sector, etc.
This report presents an overview of global market for Hepatitis A Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Hepatitis A Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Hepatitis A Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Hepatitis A Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Hepatitis A Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Hepatitis A Vaccine sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including GSK, Merck, Sanofi, Sinovac, Zhejiang Pukang, Changchun Institute of Biological, KM Biologics, IMBCA and ChangSheng, etc.
Hepatitis A Vaccine segment by Company
1. To analyze and research the global Hepatitis A Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Hepatitis A Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Hepatitis A Vaccine significant trends, drivers, influence factors in global and regions.
6. To analyze Hepatitis A Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatitis A Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hepatitis A Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatitis A Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Hepatitis A Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2019-2030).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hepatitis A Vaccine industry.
Chapter 3: Detailed analysis of Hepatitis A Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Hepatitis A Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Hepatitis A Vaccine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Chapter 10: Concluding Insights.
Two types of HAV vaccines are currently available internationally:
1. Formaldehyde-inactivated vaccines: Inactivated HAV vaccines are used in most countries. Monovalent inactivated HAV vaccines are available in paediatric dose (0.5 ml) for children aged 1 year to 15 years, and in adult dose (1 ml).
2. Live attenuated vaccines (based on H2 or LA-1 HAV strains): These vaccines are manufactured and used mainly in China and sporadically in the private sector in India.
According to APO Research, The global Hepatitis A Vaccine market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
Global Hepatitis A Vaccine key players include GSK, Merck, Sanofi, etc. Global top three manufacturers hold a share over 85%.
Europe is the largest market, with a share over 30%, followed by North America and China, both have a share about 45 percent.
In terms of product, Inactivated Vaccine is the largest segment, with a share about 70%. And in terms of application, the largest application is Government Institution, followed by Private Sector, etc.
This report presents an overview of global market for Hepatitis A Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Hepatitis A Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Hepatitis A Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Hepatitis A Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Hepatitis A Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Hepatitis A Vaccine sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including GSK, Merck, Sanofi, Sinovac, Zhejiang Pukang, Changchun Institute of Biological, KM Biologics, IMBCA and ChangSheng, etc.
Hepatitis A Vaccine segment by Company
- GSK
- Merck
- Sanofi
- Sinovac
- Zhejiang Pukang
- Changchun Institute of Biological
- KM Biologics
- IMBCA
- ChangSheng
- Convac
- Inactivated Vaccine
- Live Attenuated Vaccine
- Government Institution
- Private Sector
- Other
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
1. To analyze and research the global Hepatitis A Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Hepatitis A Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Hepatitis A Vaccine significant trends, drivers, influence factors in global and regions.
6. To analyze Hepatitis A Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatitis A Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hepatitis A Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatitis A Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Hepatitis A Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2019-2030).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hepatitis A Vaccine industry.
Chapter 3: Detailed analysis of Hepatitis A Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Hepatitis A Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Hepatitis A Vaccine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Chapter 10: Concluding Insights.
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Hepatitis A Vaccine Sales Value (2019-2030)
1.2.2 Global Hepatitis A Vaccine Sales Volume (2019-2030)
1.2.3 Global Hepatitis A Vaccine Sales Average Price (2019-2030)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 HEPATITIS A VACCINE MARKET DYNAMICS
2.1 Hepatitis A Vaccine Industry Trends
2.2 Hepatitis A Vaccine Industry Drivers
2.3 Hepatitis A Vaccine Industry Opportunities and Challenges
2.4 Hepatitis A Vaccine Industry Restraints
3 HEPATITIS A VACCINE MARKET BY COMPANY
3.1 Global Hepatitis A Vaccine Company Revenue Ranking in 2023
3.2 Global Hepatitis A Vaccine Revenue by Company (2019-2024)
3.3 Global Hepatitis A Vaccine Sales Volume by Company (2019-2024)
3.4 Global Hepatitis A Vaccine Average Price by Company (2019-2024)
3.5 Global Hepatitis A Vaccine Company Ranking, 2022 VS 2023 VS 2024
3.6 Global Hepatitis A Vaccine Company Manufacturing Base & Headquarters
3.7 Global Hepatitis A Vaccine Company, Product Type & Application
3.8 Global Hepatitis A Vaccine Company Commercialization Time
3.9 Market Competitive Analysis
3.9.1 Global Hepatitis A Vaccine Market CR5 and HHI
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
3.9.3 2023 Hepatitis A Vaccine Tier 1, Tier 2, and Tier
3.10 Mergers & Acquisitions, Expansion
4 HEPATITIS A VACCINE MARKET BY TYPE
4.1 Hepatitis A Vaccine Type Introduction
4.1.1 Inactivated Vaccine
4.1.2 Live Attenuated Vaccine
4.2 Global Hepatitis A Vaccine Sales Volume by Type
4.2.1 Global Hepatitis A Vaccine Sales Volume by Type (2019 VS 2023 VS 2030)
4.2.2 Global Hepatitis A Vaccine Sales Volume by Type (2019-2030)
4.2.3 Global Hepatitis A Vaccine Sales Volume Share by Type (2019-2030)
4.3 Global Hepatitis A Vaccine Sales Value by Type
4.3.1 Global Hepatitis A Vaccine Sales Value by Type (2019 VS 2023 VS 2030)
4.3.2 Global Hepatitis A Vaccine Sales Value by Type (2019-2030)
4.3.3 Global Hepatitis A Vaccine Sales Value Share by Type (2019-2030)
5 HEPATITIS A VACCINE MARKET BY APPLICATION
5.1 Hepatitis A Vaccine Application Introduction
5.1.1 Government Institution
5.1.2 Private Sector
5.1.3 Other
5.2 Global Hepatitis A Vaccine Sales Volume by Application
5.2.1 Global Hepatitis A Vaccine Sales Volume by Application (2019 VS 2023 VS 2030)
5.2.2 Global Hepatitis A Vaccine Sales Volume by Application (2019-2030)
5.2.3 Global Hepatitis A Vaccine Sales Volume Share by Application (2019-2030)
5.3 Global Hepatitis A Vaccine Sales Value by Application
5.3.1 Global Hepatitis A Vaccine Sales Value by Application (2019 VS 2023 VS 2030)
5.3.2 Global Hepatitis A Vaccine Sales Value by Application (2019-2030)
5.3.3 Global Hepatitis A Vaccine Sales Value Share by Application (2019-2030)
6 HEPATITIS A VACCINE MARKET BY REGION
6.1 Global Hepatitis A Vaccine Sales by Region: 2019 VS 2023 VS 2030
6.2 Global Hepatitis A Vaccine Sales by Region (2019-2030)
6.2.1 Global Hepatitis A Vaccine Sales by Region: 2019-2024
6.2.2 Global Hepatitis A Vaccine Sales by Region (2025-2030)
6.3 Global Hepatitis A Vaccine Sales Value by Region: 2019 VS 2023 VS 2030
6.4 Global Hepatitis A Vaccine Sales Value by Region (2019-2030)
6.4.1 Global Hepatitis A Vaccine Sales Value by Region: 2019-2024
6.4.2 Global Hepatitis A Vaccine Sales Value by Region (2025-2030)
6.5 Global Hepatitis A Vaccine Market Price Analysis by Region (2019-2024)
6.6 North America
6.6.1 North America Hepatitis A Vaccine Sales Value (2019-2030)
6.6.2 North America Hepatitis A Vaccine Sales Value Share by Country, 2023 VS 2030
6.7 Europe
6.7.1 Europe Hepatitis A Vaccine Sales Value (2019-2030)
6.7.2 Europe Hepatitis A Vaccine Sales Value Share by Country, 2023 VS 2030
6.8 Asia-Pacific
6.8.1 Asia-Pacific Hepatitis A Vaccine Sales Value (2019-2030)
6.8.2 Asia-Pacific Hepatitis A Vaccine Sales Value Share by Country, 2023 VS 2030
6.9 Latin America
6.9.1 Latin America Hepatitis A Vaccine Sales Value (2019-2030)
6.9.2 Latin America Hepatitis A Vaccine Sales Value Share by Country, 2023 VS 2030
6.10 Middle East & Africa
6.10.1 Middle East & Africa Hepatitis A Vaccine Sales Value (2019-2030)
6.10.2 Middle East & Africa Hepatitis A Vaccine Sales Value Share by Country, 2023 VS 2030
7 HEPATITIS A VACCINE MARKET BY COUNTRY
7.1 Global Hepatitis A Vaccine Sales by Country: 2019 VS 2023 VS 2030
7.2 Global Hepatitis A Vaccine Sales Value by Country: 2019 VS 2023 VS 2030
7.3 Global Hepatitis A Vaccine Sales by Country (2019-2030)
7.3.1 Global Hepatitis A Vaccine Sales by Country (2019-2024)
7.3.2 Global Hepatitis A Vaccine Sales by Country (2025-2030)
7.4 Global Hepatitis A Vaccine Sales Value by Country (2019-2030)
7.4.1 Global Hepatitis A Vaccine Sales Value by Country (2019-2024)
7.4.2 Global Hepatitis A Vaccine Sales Value by Country (2025-2030)
7.5 USA
7.5.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.5.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.5.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.6 Canada
7.6.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.6.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.6.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.7 Germany
7.7.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.7.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.7.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.8 France
7.8.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.8.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.8.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.9 U.K.
7.9.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.9.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.9.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.10 Italy
7.10.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.10.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.10.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.11 Netherlands
7.11.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.11.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.11.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.12 Nordic Countries
7.12.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.12.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.12.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.13 China
7.13.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.13.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.13.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.14 Japan
7.14.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.14.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.14.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.15 South Korea
7.15.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.15.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.15.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.16 Southeast Asia
7.16.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.16.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.16.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.17 India
7.17.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.17.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.17.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.18 Australia
7.18.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.18.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.18.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.19 Mexico
7.19.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.19.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.19.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.20 Brazil
7.20.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.20.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.20.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.21 Turkey
7.21.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.21.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.21.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.22 Saudi Arabia
7.22.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.22.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.22.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.23 UAE
7.23.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.23.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.23.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
8 COMPANY PROFILES
8.1 GSK
8.1.1 GSK Comapny Information
8.1.2 GSK Business Overview
8.1.3 GSK Hepatitis A Vaccine Sales, Value and Gross Margin (2019-2024)
8.1.4 GSK Hepatitis A Vaccine Product Portfolio
8.1.5 GSK Recent Developments
8.2 Merck
8.2.1 Merck Comapny Information
8.2.2 Merck Business Overview
8.2.3 Merck Hepatitis A Vaccine Sales, Value and Gross Margin (2019-2024)
8.2.4 Merck Hepatitis A Vaccine Product Portfolio
8.2.5 Merck Recent Developments
8.3 Sanofi
8.3.1 Sanofi Comapny Information
8.3.2 Sanofi Business Overview
8.3.3 Sanofi Hepatitis A Vaccine Sales, Value and Gross Margin (2019-2024)
8.3.4 Sanofi Hepatitis A Vaccine Product Portfolio
8.3.5 Sanofi Recent Developments
8.4 Sinovac
8.4.1 Sinovac Comapny Information
8.4.2 Sinovac Business Overview
8.4.3 Sinovac Hepatitis A Vaccine Sales, Value and Gross Margin (2019-2024)
8.4.4 Sinovac Hepatitis A Vaccine Product Portfolio
8.4.5 Sinovac Recent Developments
8.5 Zhejiang Pukang
8.5.1 Zhejiang Pukang Comapny Information
8.5.2 Zhejiang Pukang Business Overview
8.5.3 Zhejiang Pukang Hepatitis A Vaccine Sales, Value and Gross Margin (2019-2024)
8.5.4 Zhejiang Pukang Hepatitis A Vaccine Product Portfolio
8.5.5 Zhejiang Pukang Recent Developments
8.6 Changchun Institute of Biological
8.6.1 Changchun Institute of Biological Comapny Information
8.6.2 Changchun Institute of Biological Business Overview
8.6.3 Changchun Institute of Biological Hepatitis A Vaccine Sales, Value and Gross Margin (2019-2024)
8.6.4 Changchun Institute of Biological Hepatitis A Vaccine Product Portfolio
8.6.5 Changchun Institute of Biological Recent Developments
8.7 KM Biologics
8.7.1 KM Biologics Comapny Information
8.7.2 KM Biologics Business Overview
8.7.3 KM Biologics Hepatitis A Vaccine Sales, Value and Gross Margin (2019-2024)
8.7.4 KM Biologics Hepatitis A Vaccine Product Portfolio
8.7.5 KM Biologics Recent Developments
8.8 IMBCA
8.8.1 IMBCA Comapny Information
8.8.2 IMBCA Business Overview
8.8.3 IMBCA Hepatitis A Vaccine Sales, Value and Gross Margin (2019-2024)
8.8.4 IMBCA Hepatitis A Vaccine Product Portfolio
8.8.5 IMBCA Recent Developments
8.9 ChangSheng
8.9.1 ChangSheng Comapny Information
8.9.2 ChangSheng Business Overview
8.9.3 ChangSheng Hepatitis A Vaccine Sales, Value and Gross Margin (2019-2024)
8.9.4 ChangSheng Hepatitis A Vaccine Product Portfolio
8.9.5 ChangSheng Recent Developments
8.10 Convac
8.10.1 Convac Comapny Information
8.10.2 Convac Business Overview
8.10.3 Convac Hepatitis A Vaccine Sales, Value and Gross Margin (2019-2024)
8.10.4 Convac Hepatitis A Vaccine Product Portfolio
8.10.5 Convac Recent Developments
9 VALUE CHAIN AND SALES CHANNELS ANALYSIS
9.1 Hepatitis A Vaccine Value Chain Analysis
9.1.1 Hepatitis A Vaccine Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Hepatitis A Vaccine Sales Mode & Process
9.2 Hepatitis A Vaccine Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Hepatitis A Vaccine Distributors
9.2.3 Hepatitis A Vaccine Customers
10 CONCLUDING INSIGHTS
11 APPENDIX
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Hepatitis A Vaccine Sales Value (2019-2030)
1.2.2 Global Hepatitis A Vaccine Sales Volume (2019-2030)
1.2.3 Global Hepatitis A Vaccine Sales Average Price (2019-2030)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 HEPATITIS A VACCINE MARKET DYNAMICS
2.1 Hepatitis A Vaccine Industry Trends
2.2 Hepatitis A Vaccine Industry Drivers
2.3 Hepatitis A Vaccine Industry Opportunities and Challenges
2.4 Hepatitis A Vaccine Industry Restraints
3 HEPATITIS A VACCINE MARKET BY COMPANY
3.1 Global Hepatitis A Vaccine Company Revenue Ranking in 2023
3.2 Global Hepatitis A Vaccine Revenue by Company (2019-2024)
3.3 Global Hepatitis A Vaccine Sales Volume by Company (2019-2024)
3.4 Global Hepatitis A Vaccine Average Price by Company (2019-2024)
3.5 Global Hepatitis A Vaccine Company Ranking, 2022 VS 2023 VS 2024
3.6 Global Hepatitis A Vaccine Company Manufacturing Base & Headquarters
3.7 Global Hepatitis A Vaccine Company, Product Type & Application
3.8 Global Hepatitis A Vaccine Company Commercialization Time
3.9 Market Competitive Analysis
3.9.1 Global Hepatitis A Vaccine Market CR5 and HHI
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
3.9.3 2023 Hepatitis A Vaccine Tier 1, Tier 2, and Tier
3.10 Mergers & Acquisitions, Expansion
4 HEPATITIS A VACCINE MARKET BY TYPE
4.1 Hepatitis A Vaccine Type Introduction
4.1.1 Inactivated Vaccine
4.1.2 Live Attenuated Vaccine
4.2 Global Hepatitis A Vaccine Sales Volume by Type
4.2.1 Global Hepatitis A Vaccine Sales Volume by Type (2019 VS 2023 VS 2030)
4.2.2 Global Hepatitis A Vaccine Sales Volume by Type (2019-2030)
4.2.3 Global Hepatitis A Vaccine Sales Volume Share by Type (2019-2030)
4.3 Global Hepatitis A Vaccine Sales Value by Type
4.3.1 Global Hepatitis A Vaccine Sales Value by Type (2019 VS 2023 VS 2030)
4.3.2 Global Hepatitis A Vaccine Sales Value by Type (2019-2030)
4.3.3 Global Hepatitis A Vaccine Sales Value Share by Type (2019-2030)
5 HEPATITIS A VACCINE MARKET BY APPLICATION
5.1 Hepatitis A Vaccine Application Introduction
5.1.1 Government Institution
5.1.2 Private Sector
5.1.3 Other
5.2 Global Hepatitis A Vaccine Sales Volume by Application
5.2.1 Global Hepatitis A Vaccine Sales Volume by Application (2019 VS 2023 VS 2030)
5.2.2 Global Hepatitis A Vaccine Sales Volume by Application (2019-2030)
5.2.3 Global Hepatitis A Vaccine Sales Volume Share by Application (2019-2030)
5.3 Global Hepatitis A Vaccine Sales Value by Application
5.3.1 Global Hepatitis A Vaccine Sales Value by Application (2019 VS 2023 VS 2030)
5.3.2 Global Hepatitis A Vaccine Sales Value by Application (2019-2030)
5.3.3 Global Hepatitis A Vaccine Sales Value Share by Application (2019-2030)
6 HEPATITIS A VACCINE MARKET BY REGION
6.1 Global Hepatitis A Vaccine Sales by Region: 2019 VS 2023 VS 2030
6.2 Global Hepatitis A Vaccine Sales by Region (2019-2030)
6.2.1 Global Hepatitis A Vaccine Sales by Region: 2019-2024
6.2.2 Global Hepatitis A Vaccine Sales by Region (2025-2030)
6.3 Global Hepatitis A Vaccine Sales Value by Region: 2019 VS 2023 VS 2030
6.4 Global Hepatitis A Vaccine Sales Value by Region (2019-2030)
6.4.1 Global Hepatitis A Vaccine Sales Value by Region: 2019-2024
6.4.2 Global Hepatitis A Vaccine Sales Value by Region (2025-2030)
6.5 Global Hepatitis A Vaccine Market Price Analysis by Region (2019-2024)
6.6 North America
6.6.1 North America Hepatitis A Vaccine Sales Value (2019-2030)
6.6.2 North America Hepatitis A Vaccine Sales Value Share by Country, 2023 VS 2030
6.7 Europe
6.7.1 Europe Hepatitis A Vaccine Sales Value (2019-2030)
6.7.2 Europe Hepatitis A Vaccine Sales Value Share by Country, 2023 VS 2030
6.8 Asia-Pacific
6.8.1 Asia-Pacific Hepatitis A Vaccine Sales Value (2019-2030)
6.8.2 Asia-Pacific Hepatitis A Vaccine Sales Value Share by Country, 2023 VS 2030
6.9 Latin America
6.9.1 Latin America Hepatitis A Vaccine Sales Value (2019-2030)
6.9.2 Latin America Hepatitis A Vaccine Sales Value Share by Country, 2023 VS 2030
6.10 Middle East & Africa
6.10.1 Middle East & Africa Hepatitis A Vaccine Sales Value (2019-2030)
6.10.2 Middle East & Africa Hepatitis A Vaccine Sales Value Share by Country, 2023 VS 2030
7 HEPATITIS A VACCINE MARKET BY COUNTRY
7.1 Global Hepatitis A Vaccine Sales by Country: 2019 VS 2023 VS 2030
7.2 Global Hepatitis A Vaccine Sales Value by Country: 2019 VS 2023 VS 2030
7.3 Global Hepatitis A Vaccine Sales by Country (2019-2030)
7.3.1 Global Hepatitis A Vaccine Sales by Country (2019-2024)
7.3.2 Global Hepatitis A Vaccine Sales by Country (2025-2030)
7.4 Global Hepatitis A Vaccine Sales Value by Country (2019-2030)
7.4.1 Global Hepatitis A Vaccine Sales Value by Country (2019-2024)
7.4.2 Global Hepatitis A Vaccine Sales Value by Country (2025-2030)
7.5 USA
7.5.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.5.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.5.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.6 Canada
7.6.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.6.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.6.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.7 Germany
7.7.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.7.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.7.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.8 France
7.8.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.8.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.8.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.9 U.K.
7.9.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.9.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.9.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.10 Italy
7.10.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.10.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.10.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.11 Netherlands
7.11.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.11.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.11.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.12 Nordic Countries
7.12.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.12.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.12.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.13 China
7.13.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.13.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.13.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.14 Japan
7.14.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.14.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.14.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.15 South Korea
7.15.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.15.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.15.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.16 Southeast Asia
7.16.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.16.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.16.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.17 India
7.17.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.17.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.17.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.18 Australia
7.18.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.18.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.18.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.19 Mexico
7.19.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.19.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.19.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.20 Brazil
7.20.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.20.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.20.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.21 Turkey
7.21.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.21.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.21.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.22 Saudi Arabia
7.22.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.22.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.22.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
7.23 UAE
7.23.1 Global Hepatitis A Vaccine Sales Value Growth Rate (2019-2030)
7.23.2 Global Hepatitis A Vaccine Sales Value Share by Type, 2023 VS 2030
7.23.3 Global Hepatitis A Vaccine Sales Value Share by Application, 2023 VS 2030
8 COMPANY PROFILES
8.1 GSK
8.1.1 GSK Comapny Information
8.1.2 GSK Business Overview
8.1.3 GSK Hepatitis A Vaccine Sales, Value and Gross Margin (2019-2024)
8.1.4 GSK Hepatitis A Vaccine Product Portfolio
8.1.5 GSK Recent Developments
8.2 Merck
8.2.1 Merck Comapny Information
8.2.2 Merck Business Overview
8.2.3 Merck Hepatitis A Vaccine Sales, Value and Gross Margin (2019-2024)
8.2.4 Merck Hepatitis A Vaccine Product Portfolio
8.2.5 Merck Recent Developments
8.3 Sanofi
8.3.1 Sanofi Comapny Information
8.3.2 Sanofi Business Overview
8.3.3 Sanofi Hepatitis A Vaccine Sales, Value and Gross Margin (2019-2024)
8.3.4 Sanofi Hepatitis A Vaccine Product Portfolio
8.3.5 Sanofi Recent Developments
8.4 Sinovac
8.4.1 Sinovac Comapny Information
8.4.2 Sinovac Business Overview
8.4.3 Sinovac Hepatitis A Vaccine Sales, Value and Gross Margin (2019-2024)
8.4.4 Sinovac Hepatitis A Vaccine Product Portfolio
8.4.5 Sinovac Recent Developments
8.5 Zhejiang Pukang
8.5.1 Zhejiang Pukang Comapny Information
8.5.2 Zhejiang Pukang Business Overview
8.5.3 Zhejiang Pukang Hepatitis A Vaccine Sales, Value and Gross Margin (2019-2024)
8.5.4 Zhejiang Pukang Hepatitis A Vaccine Product Portfolio
8.5.5 Zhejiang Pukang Recent Developments
8.6 Changchun Institute of Biological
8.6.1 Changchun Institute of Biological Comapny Information
8.6.2 Changchun Institute of Biological Business Overview
8.6.3 Changchun Institute of Biological Hepatitis A Vaccine Sales, Value and Gross Margin (2019-2024)
8.6.4 Changchun Institute of Biological Hepatitis A Vaccine Product Portfolio
8.6.5 Changchun Institute of Biological Recent Developments
8.7 KM Biologics
8.7.1 KM Biologics Comapny Information
8.7.2 KM Biologics Business Overview
8.7.3 KM Biologics Hepatitis A Vaccine Sales, Value and Gross Margin (2019-2024)
8.7.4 KM Biologics Hepatitis A Vaccine Product Portfolio
8.7.5 KM Biologics Recent Developments
8.8 IMBCA
8.8.1 IMBCA Comapny Information
8.8.2 IMBCA Business Overview
8.8.3 IMBCA Hepatitis A Vaccine Sales, Value and Gross Margin (2019-2024)
8.8.4 IMBCA Hepatitis A Vaccine Product Portfolio
8.8.5 IMBCA Recent Developments
8.9 ChangSheng
8.9.1 ChangSheng Comapny Information
8.9.2 ChangSheng Business Overview
8.9.3 ChangSheng Hepatitis A Vaccine Sales, Value and Gross Margin (2019-2024)
8.9.4 ChangSheng Hepatitis A Vaccine Product Portfolio
8.9.5 ChangSheng Recent Developments
8.10 Convac
8.10.1 Convac Comapny Information
8.10.2 Convac Business Overview
8.10.3 Convac Hepatitis A Vaccine Sales, Value and Gross Margin (2019-2024)
8.10.4 Convac Hepatitis A Vaccine Product Portfolio
8.10.5 Convac Recent Developments
9 VALUE CHAIN AND SALES CHANNELS ANALYSIS
9.1 Hepatitis A Vaccine Value Chain Analysis
9.1.1 Hepatitis A Vaccine Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Hepatitis A Vaccine Sales Mode & Process
9.2 Hepatitis A Vaccine Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Hepatitis A Vaccine Distributors
9.2.3 Hepatitis A Vaccine Customers
10 CONCLUDING INSIGHTS
11 APPENDIX
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
